Lobe Sciences Ltd.
OTC: LOBEF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Frederick Dominick Sancilio
- Headquarters
- Vancouver, Canada
- IPO year
- 2023
- Market cap
- $1.2M
- Website
- https://www.lobesciences.com
Loading LOBEF…
Loading profile data…Frequently asked questions about LOBEF
What does Lobe Sciences Ltd. (LOBEF) do?
Lobe Sciences Ltd. is a life sciences company focused on researching and advancing psychedelic-based medicines. Their primary therapeutic development involves psilocybin-derived treatments combined with N-acetylcysteine, specifically for addressing mild traumatic brain injuries (mTBI) and post-traumatic stress disorder (PTSD). Additionally, they...
Where does LOBEF trade?
Lobe Sciences Ltd. (LOBEF) trades on the Other OTC.
What sector is LOBEF in?
Lobe Sciences Ltd. (LOBEF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Lobe Sciences Ltd.?
Frederick Dominick Sancilio is the chief executive officer of Lobe Sciences Ltd. (LOBEF).
Where is Lobe Sciences Ltd. headquartered?
Lobe Sciences Ltd. is headquartered in Canada.
Does LOBEF pay a dividend?
Lobe Sciences Ltd. (LOBEF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LOBEF go public?
Lobe Sciences Ltd. (LOBEF) completed its initial public offering in 2023.